Canaccord raised the firm’s price target on Progyny (PGNY) to $23 from $21 and keeps a Hold rating on the shares. The firm said with a solid 2Q beat and guidance raise on August 7, Progyny is getting its mojo back as it tries to restore investor confidence after last year’s utilization and consumption variability, and the loss of Amazon’s (AMZN) large book-of-business.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny’s Earnings Call Highlights Robust Growth and Strategic Partnerships
- Strong Financial Performance and Market Trends Support Buy Rating for Progyny
- Progyny, Inc. Reports Record Q2 2025 Revenue
- Progyny reports Q2 adjusted EPS 48c, consensus 43c
- Progyny sees Q3 adjusted EPS 37c-40c, consensus 37c